DelveInsight’s “Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Get a Free sample for the Aplastic Anemia Market Report
https://www.delveinsight.com/sample-request/aplastic-anemia-market
Some of the key facts of the Aplastic Anemia Market Report:
-
The Aplastic Anemia market size was valued approximately USD 270 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
-
In December 2025, Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent organization of Gamida Cell Inc., a pioneer in cell therapy innovation, has announced that the U.S. Food and Drug Administration (“FDA”) has approved Omisirge (Omidubicel-onlv) for treating Severe Aplastic Anemia (SAA).
-
In September 2025, Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy sourced from cord blood. Marketed as Omisirge®, it is approved for adults and pediatric patients aged 12 and older with hematologic malignancies who are scheduled for umbilical cord blood transplantation following myeloablative conditioning, aiming to shorten neutrophil recovery time and lower the risk of infection.
-
Japan holds the position of the second-largest market for aplastic anemia among the 7MM. In 2023, the market size for aplastic anemia in Japan was approximately USD 35 million and is anticipated to grow during the forecast period.
-
Throughout the forecast period, the increase in the aplastic anemia market size is expected to be driven by pipeline candidates like Omidubicel-onlv, REGN7257, and ALVAIZ (eltrombopag choline).
-
In 2023, Germany holds the largest market size among the EU4 and the UK, with approximately USD 14 million, followed by France.
-
In 2023, around 56% of aplastic anemia cases in the 7MM were reported in individuals aged 60 and above, with the remaining 43% occurring in those under 60.
-
In the EU4 nations, Germany had the highest estimated incident cases of aplastic anemia, comprising approximately [insert percentage here].
-
Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others
-
Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others
-
The Aplastic Anemia epidemiology based on gender analyzed that the male-to-female ratio is approximately 1:1
-
The Aplastic Anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aplastic Anemia pipeline products will significantly revolutionize the Aplastic Anemia market dynamics.
Aplastic Anemia Overview
According to the National Institutes of Health, pancytopenia and decreased or nonexistent hematopoietic precursors in the bone marrow are symptoms of aplastic anaemia, which is a state of chronic primary hematopoietic failure brought on by damage.
To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast
Aplastic Anemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Aplastic Anemia Epidemiology Segmentation:
The Aplastic Anemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Aplastic Anemia
-
Prevalent Cases of Aplastic Anemia by severity
-
Gender-specific Prevalence of Aplastic Anemia
-
Diagnosed Cases of Episodic and Chronic Aplastic Anemia
Aplastic Anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aplastic Anemia market or expected to get launched during the study period. The analysis covers Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Aplastic Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Aplastic Anemia Therapies and Key Companies
-
ALVAIZ (eltrombopag choline): Teva Pharmaceuticals
-
REGN7257: Regeneron Pharmaceuticals
-
PF-06462700: Pfizer
-
Omidubicel: Gamida-Cell
-
Romiplostim: Kyowa Kirin
-
Eltrombopag: Novartis
-
AMG531: Kyowa Kirin
-
Eltrombopag: Novartis
-
Hetrombopag Olamine: Jiangsu HengRui Medicine Co., Ltd.
-
Ibrutinib: Janssen Scientific Affairs, LLC
Discover more about therapies set to grab major Aplastic Anemia market share @ Aplastic Anemia Treatment Market
Aplastic Anemia Market Drivers
-
Increasing awareness and improved diagnosis: Greater awareness among healthcare professionals and advancements in diagnostic techniques are leading to earlier and more accurate detection of aplastic anemia.
-
Advancements in treatment options: The development of immunosuppressive therapies, hematopoietic stem cell transplantation, and novel targeted therapies is improving patient outcomes and driving market growth.
-
Growing investment in rare disease research: Pharmaceutical companies and research organizations are increasing investments in rare hematologic disorders, supporting new drug development.
-
Rising healthcare expenditure: Improved access to advanced healthcare facilities and treatment options is contributing to increased adoption of therapies.
Aplastic Anemia Market Barriers
-
High cost of treatment: Advanced therapies such as stem cell transplantation and long-term immunosuppressive treatments can be expensive, limiting accessibility.
-
Limited donor availability for transplantation: Successful hematopoietic stem cell transplantation often depends on compatible donors, which can restrict treatment options.
-
Adverse effects associated with therapies: Immunosuppressive treatments and transplantation procedures may cause significant side effects and complications.
-
Limited patient population: As a rare disease, the smaller patient pool may restrict market expansion and reduce commercial incentives for drug development.
-
Regulatory and clinical trial challenges: Stringent regulatory requirements and difficulties in recruiting patients for trials can delay the approval of new therapies.
Scope of the Aplastic Anemia Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others
-
Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others
-
Aplastic Anemia Therapeutic Assessment: Aplastic Anemia current marketed and Aplastic Anemia emerging therapies
-
Aplastic Anemia Market Dynamics: Aplastic Anemia market drivers and Aplastic Anemia market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Aplastic Anemia Unmet Needs, KOL’s views, Analyst’s views, Aplastic Anemia Market Access and Reimbursement
To know more about Aplastic Anemia companies working in the treatment market, visit @ Aplastic Anemia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Aplastic Anemia Market Report Introduction
2. Executive Summary for Aplastic Anemia
3. SWOT analysis of Aplastic Anemia
4. Aplastic Anemia Patient Share (%) Overview at a Glance
5. Aplastic Anemia Market Overview at a Glance
6. Aplastic Anemia Disease Background and Overview
7. Aplastic Anemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Aplastic Anemia
9. Aplastic Anemia Current Treatment and Medical Practices
10. Aplastic Anemia Unmet Needs
11. Aplastic Anemia Emerging Therapies
12. Aplastic Anemia Market Outlook
13. Country-Wise Aplastic Anemia Market Analysis (2020–2034)
14. Aplastic Anemia Market Access and Reimbursement of Therapies
15. Aplastic Anemia Market Drivers
16. Aplastic Anemia Market Barriers
17. Aplastic Anemia Appendix
18. Aplastic Anemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
